PAI Pharma (“PAI”), a portfolio company of Olympus Partners and a leading U.S. developer, manufacturer and marketer of oral liquid medicines, announces the acquisition of Nivagen Pharmaceuticals, Inc. (“Nivagen”), a California-based pharmaceutical company with advanced aseptic manufacturing infrastructure and a robust pipeline of ready-to-use sterile injectables. The acquisition marks a significant step forward in PAI’s strategy to expand domestic pharmaceutical manufacturing, strengthen supply-chain resilience, and accelerate growth in RTU sterile injectable and hospital-focused therapies, areas that continue to face persistent drug shortages across the U.S. healthcare system.
Read the full article: PAI Pharma Acquires Nivagen Pharmaceuticals //
Source: https://www.prnewswire.com/news-releases/pai-pharma-acquires-nivagen-pharmaceuticals-expanding-domestic-sterile-injectable-manufacturing-and-expanding-ready-to-use-rtu-product-offering-in-the-hospital-market-302654196.html